- Home
- LUCD vs NKTX Comparison
LUCD vs NKTX Comparison
Compare LUCD & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- NKTX
- Stock Information
- Founded
- LUCD 2018
- NKTX 2015
- Country
- LUCD United States
- NKTX United States
- Employees
- LUCD N/A
- NKTX N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- NKTX Health Care
- Exchange
- LUCD Nasdaq
- NKTX Nasdaq
- Market Cap
- LUCD 112.5M
- NKTX 123.5M
- IPO Year
- LUCD 2021
- NKTX 2020
- Fundamental
- Price
- LUCD $1.02
- NKTX $2.33
- Analyst Decision
- LUCD Strong Buy
- NKTX Strong Buy
- Analyst Count
- LUCD 4
- NKTX 5
- Target Price
- LUCD $3.94
- NKTX $13.50
- AVG Volume (30 Days)
- LUCD 704.2K
- NKTX 553.5K
- Earning Date
- LUCD 08-13-2025
- NKTX 08-12-2025
- Dividend Yield
- LUCD N/A
- NKTX N/A
- EPS Growth
- LUCD N/A
- NKTX N/A
- EPS
- LUCD N/A
- NKTX N/A
- Revenue
- LUCD $4,360,000.00
- NKTX N/A
- Revenue This Year
- LUCD $49.70
- NKTX N/A
- Revenue Next Year
- LUCD $198.20
- NKTX N/A
- P/E Ratio
- LUCD N/A
- NKTX N/A
- Revenue Growth
- LUCD 14.74
- NKTX N/A
- 52 Week Low
- LUCD $0.73
- NKTX $1.31
- 52 Week High
- LUCD $1.80
- NKTX $6.63
- Technical
- Relative Strength Index (RSI)
- LUCD 44.17
- NKTX 65.48
- Support Level
- LUCD $0.96
- NKTX $1.96
- Resistance Level
- LUCD $1.03
- NKTX $2.26
- Average True Range (ATR)
- LUCD 0.06
- NKTX 0.14
- MACD
- LUCD 0.00
- NKTX 0.01
- Stochastic Oscillator
- LUCD 43.75
- NKTX 77.32
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.